Table 3.
Treatments used for the management of Kaposi’s sarcoma in HIV-patients with suppressed viremia, in addition to combined antiretroviral therapy, and clinical outcomes, in the main published series.
| Reference | Mani, J Int Assoc Physicians AIDS Care, 2009 [6] (n = 20) | Palich, Clin Infect Dis, 2019 [7] (n = 21) | Severin, AIDS, 2021 [8] (n = 12) |
|---|---|---|---|
| All cytotoxic treatments | 14 (70%) | 21 (100%) | 2 (17%) |
| Liposomal doxorubicine | 13 (65%) | 19 (90%) | - |
| Paclitaxel | 3 (15%) | 10 (48%) | - |
| Bleomycin | - | 2 (10%) | - |
| Vincristine | - | 1 (5%) | - |
| Antivascular endothelial growth factors | - | 5 (24%) | - |
| Interferon-alfa | - | 2 (10%) | - |
| All local treatments | 4 (20%) | 1 (5%) | 4 (33%) |
| Radiotherapy | 4 (20%) | 1 (5%) | 1 (8%) |
| Cryotherapy | - | - | 1 (8%) |
| Retinoid | - | - | 1 (8%) |
| Laser | - | - | 1 (8%) |
| Unspecified other treatment | 5 (25%) | - | - |
| Clinical surveillance only | 1 (5%) | - | 5 (42%) |
| Clinical outcomes | |||
| Follow-up duration, months, median | 39 (range: 6–120) | 17 (interquartile: 9–20) | - |
| Complete or partial regression | 13/20 (65%) | 6/16 (37%) | - |
| Stable disease | 4/20 (20%) | 6/16 (38%) | - |
| Progression | 3/20 (15%) | 4/16 (25%) | - |